QIAGEN Presents QIAsymphony Connect & Oncology Innovations at AMP 2025

11/10/2025 – 01:30 AM

• QIAsymphony Connect, the next generation of automated nucleic acid purification platform, to be shown at AMP 2025 as early access phase begins ahead of full release in mid-2026
• QIAGEN showcases Sample to Insight workflows for comprehensive genomic profiling (CGP) based on Element Biosciences Trinity™ technology
• Partnership with Myriad Genetics Inc. to highlight development of a homologous recombination deficiency (HRD) assay for use in cancer profiling

GERMANTOWN, Md. & VENLO, Netherlands– QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced the debut of QIAsymphony Connect, the next generation of QIAGEN’s widely adopted automated nucleic acid purification platform, at the 2025 AMP (Association for Molecular Pathology) annual meeting from November 11-15 in Boston.

The unveiling of QIAsymphony Connect builds on the foundation of over 3,000 installations of its predecessor by the end of 2024. This new iteration is engineered to bolster liquid biopsy applications, boasting enhanced speed, superior sample traceability, and advanced digital connectivity for diagnostic laboratories. This technological upgrade stands to streamline lab processes and improve data management, potentially driving down operational costs and accelerating research outcomes.

Beyond QIAsymphony Connect, QIAGEN’s presence at AMP will spotlight a suite of product innovations and strategic partnership updates within the precision oncology space. These advancements underscore the company’s commitment to delivering comprehensive Sample to Insight solutions tailored for both research and clinical applications. The focus on precision oncology reflects a broader industry trend toward personalized medicine, where diagnostic tools are increasingly used to guide treatment decisions based on an individual’s unique genetic profile.

“In an era where labs are under mounting pressure to analyze increasingly complex samples with heightened precision and speed, QIAsymphony Connect is strategically designed to address these evolving demands,” stated Nitin Sood, Senior Vice President and Head of Product Portfolio & Innovation at QIAGEN. “Our presence at AMP 2025 underscores our dedication to advancing high-growth areas in sample technologies. QIAGEN is at the forefront, supporting customers globally with cutting-edge liquid biopsy applications and collaborating with partners to pioneer breakthroughs in precision oncology.” This statement highlights QIAGEN’s proactive approach to addressing the challenges faced by modern diagnostic labs, suggesting a strong market orientation and responsiveness to customer needs.

QIAsymphony Connect: Revolutionizing Automated Sample Preparation

QIAsymphony Connect leverages several key improvements to enhance performance, accelerate processing times, and bolster connectivity across a diverse range of diagnostic and research workflows:

• Superior extraction performance: An enhanced elution process reduces intrinsic dead volume, resulting in higher nucleic acid concentrations and maximizing recovery from large sample volumes. This improvement is crucial for applications requiring high sensitivity, such as early cancer detection.
• Higher throughput: Enables processing of up to 50% more samples in specific liquid biopsy protocols, thereby boosting productivity and output without compromising data quality. This feature is particularly valuable for labs handling high volumes of samples, potentially leading to increased revenue and faster turnaround times.
• Optimized for high-sensitivity oncology applications: Specifically designed for workflows such as minimal residual disease (MRD) monitoring, where processing large sample volumes and achieving small elution volumes are essential for early and accurate detection.
• Full sample traceability: Automated 2D barcode scanning for both sample and eluate tubes ensures reliable end-to-end tracking, minimizing errors and enhancing data integrity. This feature is increasingly important in regulated environments where traceability is a critical concern.
• Seamless connectivity: Integrates seamlessly with Laboratory Information Management Systems (LIMS) and QIAsphere, QIAGEN’s cloud-based platform for remote monitoring and workflow optimization. This connectivity enhances data sharing and collaboration, facilitating more efficient research and diagnostic processes.
• Enhanced operational efficiency: Supports improved scalability and integration across various laboratory processes, allowing labs to adapt to changing needs and scale their operations more effectively.

QIAsymphony Connect is currently available to select customers through an early access program, with a full commercial release slated for mid-2026. The existing QIAsymphony platform will remain available for purchase during this transition period, ensuring continuity for current users. This phased rollout allows QIAGEN to gather feedback and refine the product before its widespread release, potentially mitigating risks and ensuring a smoother adoption process.

Driving Progress in Precision Oncology

QIAGEN is showcasing advancements across its Sample to Insight workflows, including early-access data and developments stemming from two significant precision oncology partnerships. This strategic focus on partnerships underscores the growing importance of collaboration in the rapidly evolving field of genomics and personalized medicine.

• A joint workshop with Element Biosciences on November 12 will feature early-access data demonstrating an efficient, scalable, comprehensive genomic profiling workflow for characterizing breast cancer FFPE samples using the QIAseq xHYB Trinity CGP on the Element Biosciences Trinity technology, together with CLC Genomics Workbench and QCI Interpret. Commercial launch is anticipated in early 2026. This collaboration leverages the strengths of both companies, combining QIAGEN’s expertise in sample preparation and bioinformatics with Element Biosciences’ innovative sequencing technology.
• Data from the collaboration with Myriad Genetics Inc. will also be presented at AMP. The two companies are collaborating to advance testing for homologous recombination deficiency (HRD), a genetic condition that may make certain cancers more responsive to targeted therapies. Early results from the QIAseq xHYB HRD Panel (intended for research applications) demonstrate high concordance with Myriad Genetics’ MyChoice^® CDx assay. Full commercialization (excluding Japan) is expected in early 2026. This partnership addresses a critical need in cancer diagnostics, providing clinicians with more accurate tools to identify patients who may benefit from specific treatments.

The QIAseq xHYB HRD Panel can be used in conjunction with the QIAseq xHYB CGP Panel to enable comprehensive genomic profiling and advanced HRD detection within a single hybrid-capture workflow. This combined assay allows for simultaneous analysis of SNVs, indels, and CNVs across 724 cancer-relevant genes, while also assessing key therapy biomarkers, including BRCA1/2, HRD, MSI, and TMB. This comprehensive approach offers significant advantages in terms of efficiency and cost-effectiveness, potentially making advanced genomic profiling more accessible to a wider range of patients and healthcare providers.

QIAGEN’s strategic focus on automation, coupled with its emphasis on precision oncology through product innovation and key partnerships, positions the company to capitalize on the growing demand for personalized medicine solutions. The launch of QIAsymphony Connect represents a significant step forward in the automation of sample preparation, while the collaborations with Element Biosciences and Myriad Genetics underscore the importance of partnerships in driving innovation and expanding the reach of advanced diagnostic technologies.

Source: QIAGEN N.V.